BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
101.61
-0.47 (-0.46%)
At close: Aug 31, 2026, 4:00 PM EDT
102.00
+0.39 (0.38%)
After-hours: Aug 31, 2026, 7:53 PM EDT
BioNTech SE Revenue
BioNTech SE had revenue of 145.80M EUR in the quarter ending June 30, 2026, a decrease of -56.99%. This brings the company's revenue in the last twelve months to 2.43B, down -15.71% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.
Revenue (ttm)
2.43B EUR
Revenue Growth
-15.71%
P/S Ratio
8.43
Revenue / Employee
310,785 EUR
Employees
7,807
Market Cap
25.52B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| Royalty Pharma | 2.54B |
| Ascendis Pharma | 1.20B |
| Insmed | 1.14B |
BNTX News
- 20 hours ago - BioNTech price target lowered to $136 from $142 at Canaccord - TheFly
- 3 days ago - BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why - TipRanks
- 3 days ago - Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital - TheFly
- 3 days ago - mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley - TheFly
- 3 days ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 3 days ago - BioNTech drops 9% after ending Phase 2 colorectal cancer trial - TheFly
- 3 days ago - BioNTech to terminate Phase 2 monotherapy trial of cevumeran - TheFly
- 4 days ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters